Gilead Sciences EBIT

Gilead Sciences (GILD.SW) currently reports a EBIT of $-1.7B as of June 2026. That compares with $8.2B in the prior-year period — down 120.4% year over year. That is below the Healthcare sector average of $110B. Use the charts on this page to explore Gilead Sciences's EBIT history and peer comparisons.

Gilead Sciences's EBIT decreased from $8.2B to $-1.7B — a 120.4% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Gilead Sciences's EBIT of $-1.7B is lower than the Healthcare sector average of $110B. That is roughly 101.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Gilead Sciences reported $-1.7B in EBIT as of June 2026. That compares with $8.2B in the prior-year period — down 120.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-1.7B, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for Gilead Sciences, and consider following GILD.SW for alerts when major investors trade the stock.